Seeking Alpha
01 Aug 2026, 18:12 UTC · 15w ago
Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating
Impact · against what's priced in
Collegium is shifting its valuation narrative from a pain-management company to a broader CNS platform via the AZSTARYS acquisition. The move is supported by concrete 2026 EBITDA guidance of $475–500M and significant synergy targets, though it introduces $300M in new debt.
- COLL+0.60
No priced-in read yet
- In context
The transition to a CNS platform and the acquisition of AZSTARYS provide a new growth lever, with 2026 revenue targets of $865–895M and projected annual synergies exceeding $50M.
Read from the article alone

Search tags




